The present invention provides a humanized antibody or an antigen-binding fragment thereof that binds to a HEG1 protein, in which the antibody is capable of binding to a human HEG1 protein expressed in mesothelioma cells.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
2.
HUMANIZED ANTIBODY THAT BINDS TO HEG1 PROTEIN AND COMPLEX OF ANTIBODY AND RADIONUCLIDE
The present invention provides a humanized antibody that binds to a HEG1 protein and a complex of the antibody and a radionuclide. According to the present invention, there is a complex including an antibody, and a radionuclide, in which the antibody is a humanized antibody capable of binding a human HEG1 protein expressed on mesothelioma cells.
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
3.
Biomarker for Detecting Hepatocytes With Bile Ductular Proliferation
National University Corporation Kanazawa University (Japan)
Inventor
Seiki, Motoharu
Yamashita, Taro
Okada, Hikari
Kaneko, Shuichi
Koshikawa, Naohiko
Funahashi, Nobuaki
Abstract
The present invention provides a method of detecting a biomarker for detecting hepatocytes with bile ductular proliferation, the method including: detecting laminin γ2 single chain or a nucleic acid encoding the same as the biomarker in a specimen.
TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (Japan)
TOKYO UNIVERSITY OF SCIENCE FOUNDATION (Japan)
NATIONAL CANCER CENTER (Japan)
NIPPON MEDICAL SCHOOL FOUNDATION (Japan)
Inventor
Terao, Yasuhisa
Yoshida, Emiko
Kato, Hisamori
Ohtsu, Takashi
Ueno, Yuta
Kawaji, Hideya
Sozu, Takashi
Kato, Tomoyasu
Abstract
The purpose of the present invention is to provide a method for evaluating the occurrence of lymph node metastasis of endometrial cancer or the lymph node metastasis capability of endometrial cancer with high accuracy. Provided is a method for evaluating the occurrence of lymph node metastasis of endometrial cancer, or the lymph node metastasis capability of endometrial cancer or the prognosis of endometrial cancer, the method comprising measuring a value of a specific parameter, then introducing the value to a model that is constructed by machine learning, and then evaluating the occurrence of lymph node metastasis of endometrial cancer, or the lymph node metastasis capability of endometrial cancer or the prognosis of endometrial cancer, in which the model is constructed by machine learning employing a value of the parameter in each patient in a teacher sample group including endometrial cancer patients with lymph node metastasis and endometrial cancer patients without lymph node metastasis as an explanatory variable and also employing data about the presence or absence of lymph node metastasis in each patient in the group as an objective variable.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
5.
LAMC2-NR6A1 Splicing Variant and Translation Product Thereof
The present invention relates to a splicing variant derived from exon 12 of laminin γ2 (LAMC2) gene and intron 1 of the antisense strand of NR6A1 gene.
C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
6.
EVALUATION METHOD, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, RECORDING MEDIUM, EVALUATION SYSTEM AND TERMINAL DEVICE FOR RELATIVE PHARMACOLOGICAL ACTION OF COMBINATION OF IMMUNE CHECKPOINT INHIBITOR WITH ANTICANCER DRUG AS CONCOMITANT DRUG COMPARED TO PHARMACOLOGICAL ACTION OF IMMUNE CHECKPOINT INHIBITOR ALONE
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (Japan)
Inventor
Azuma, Koichi
Murotani, Kenta
Sasada, Tetsuro
Tagami, Tomoyuki
Hagiwara, Asami
Imaizumi, Akira
Karakawa, Sachise
Kawasaki, Mika
Miyagi, Yohei
Tamura, Tomohiko
Saito, Haruhiro
Nakahara, Yoshiro
Wei, Feifei
Kasajima, Rika
Xiang, Huihui
Ban, Tatsuma
Abstract
The present invention addresses the problem of providing an evaluation method, etc., capable of providing reliable information that can be used as a reference for understanding an individual difference in the expression of the relative pharmacological action of a combination of an immune checkpoint inhibitor with an anticancer drug, which is a concomitant agent, compared to the pharmacological action of the immune checkpoint inhibitor alone. The present embodiment evaluates the relative pharmacological action of a combination of an immune checkpoint inhibitor with an anticancer drug, which is a concomitant agent, in a subject to be evaluated, compared to the pharmacological action of the immune checkpoint inhibitor alone, by using the concentration of at least one metabolite selected from among Glu, Arg, Orn, Cit, His, Val, Phe, Tyr, Met, Pro, Asn, Leu, Lys, Thr, Ile, Gln, Ala, Ser, a-ABA, Trp, Gly, AnthA, hKyn, hTrp, Kyn, KynA, NP, QA and XA in the blood of the subject to be evaluated.
NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (Japan)
Inventor
Seiki, Motoharu
Yamashita, Taro
Okada, Hikari
Kaneko, Shuichi
Koshikawa, Naohiko
Funahashi, Nobuaki
Abstract
The present invention provides a method for detecting a biomarker for detecting hepatocytes with bile ductular proliferation, said method comprising a step for detecting laminin γ2 single chain or a nucleic acid encoding the same as the biomarker in a specimen.
The present invention provides a humanized antibody capable of binding to HEG1 protein or an antigen-binding fragment thereof, the antibody being a humanized antibody capable of binding to human HEG1 protein expressed in a mesothelioma cell.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides: a humanized antibody capable of binding to HEG1 protein; and a complex of the antibody and a radioactive nuclear species. According to the present invention, a complex comprising an antibody and a radioactive nuclear species is provided, in which the antibody is a humanized antibody capable of binding to human HEG1 protein expressed in a mesothelioma cell.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
Provided are a technique for assessing the recurrence risk of endometrial cancer and a method for using the same. A method for assessing the recurrence risk of endometrial cancer, said method comprising a step for measuring the expression level of at least one selected from the group consisting of PGR and ERα in a biosample derived from a cancer tissue isolated from an endometrial cancer patient. A method for assessing lymph node metastasis, lymph node metastasis ability or prognosis of endometrial cancer, said method comprising a step for measuring the expression level of at least one selected from the group consisting of PGR and ERα and the expression level of at least one selected from the group consisting of SEMA3D and TACC2 in a biosample derived from a cancer tissue isolated from an endometrial cancer patient.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to a splicing variant derived from exon 12 of the Laminin γ2 (LAMC2) gene and intron 1 of the antisense strand of the NR6A1 gene.
A61P 35/04 - Antineoplastic agents specific for metastasis
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
Provided is a novel cancer marker for testing the risk of developing a cancer. This cancer marker includes at least one substance selected from the group consisting of anti-HIRIP3 antibodies, HIRIP3, anti-FNDC11 antibodies, FNDC11, anti-SLC1A3 antibodies, SLC1A3, anti-TMEM33 antibodies, TMEM33, anti-ABCF1 antibodies, ABCF1, anti-CFDP1 antibodies, CFDP1, anti-POLR3GL antibodies, POLR3GL, anti-CADM1 antibodies, CADM1, anti-RNF128 antibodies, RNF128, anti-ATP6V1B1 antibodies, and ATP6V1B1.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
Problem: The problem addressed by the present invention is to obtain a drug effect not obtained by conventional peptide vaccines which cause CD8+ CTL to activate and proliferate, by administering a class II epitope as a peptide vaccine. Solution: The inventors of the present invention discovered as a result of in-depth studies of the above problems that these problems can be solved acquiring a peptide that has a partial amino acid sequence containing a mutant amino acid of a neoantigen expressed by cancer cells and is an epitope presented by a class II molecule. Selected drawing: none
The purpose of the invention is to provide a method for identifying molecules involved in refractory cancers. Furthermore, the purpose of the invention is to provide a method for identifying drugs effective against refractory cancers. Additionally, the purpose of the invention is to provide a drug effective against recurrent cancers. Provided is a method for screening for molecules involved in refractory cancers, wherein the expression level of an EMT-associated molecule at pre- and post-administration of an anticancer agent is measured in stromal cells and/or cancer cells in tissue that reconstructs the cancer microenvironment, and an EMT-associated molecule presenting a higher expression level at post-administration of the anticancer agent than at pre-administration is scored as being involved in refractory cancers. Also provided is a method for screening for drugs effective against refractory cancers, wherein the expression level of an EMT-associated molecule at pre- and post-administration of an anticancer agent is measured in stromal cells and/or cancer cells in tissue that reconstructs the cancer microenvironment, and an EMT-associated molecule presenting a higher expression level at post-administration of the anticancer agent than at pre-administration is scored as being involved in refractory cancers, while a substance that can inhibit the function of this EMT-associated molecule is scored as a drug effective against refractory cancers. Further provided is a drug for treating and/or preventing tumor recurrence as a combination of an anticancer agent with an inhibitor targeted to the NOTCH3 signal.
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided is a technique for accurately evaluating the prognosis of a cancer. This method comprises: measuring the expression level of an EMT-related molecule in cancer cells and stromal cells in a cancer tissue from a patient or a tissue reconstructing the cancer microenvironment including cancer cells from the patient; and predicting the prognosis of the patient on the basis of this level.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
The present disclosure provides a biomarker for prognostic prediction of cancer immunotherapy by an immune checkpoint inhibitory drug, the biomarker being one or more selected from the group consisting of CXCL2, VEGF, CHI3L1, IFNα2, GM-CSF, and MMP2.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
17.
HLA-A24-RESTRICTED EPITOPE PEPTIDE DERIVED FROM METHOTHELIN
Provided is an HLA-A24-restricted epitope peptide derived from methothelin. More specifically, provided are a peptide comprising an amino acid sequence AFYPGYLCSL (SEQ ID NO: 15), a polynucleotide encoding the peptide represented by SEQ ID NO: 15, and an expression vector containing the polynucleotide.
One embodiment of this invention is a method for confirming expression of the PRDM14 gene from blood or lymphatic fluid collected from a subject by: (1) detecting PRDM14 positive CTC which expresses the PRDM14 gene; or (2) measuring the concentration of at least one protein selected from the group consisting of leptin receptor (LEPR), macrophage-derived chemokine (MDC) and gamma-interferon (IFNγ).
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The present invention provides an antibody for detecting mesothelioma and an antibody having high specificity to mesothelioma and high sensitivity thereto. The present invention also provides a method of diagnosis of mesothelioma by using the antibody, a reagent containing the antibody for use in diagnosis of mesothelioma, and a kit comprising the antibody for use in diagnosis of mesothelioma. Further, the present invention provides a marker for use in diagnosis of mesothelioma. Furthermore, the present invention provides a pharmaceutical composition containing the antibody according to the present invention or an antigen-binding fragment thereof for use in treatment of mesothelioma. An antibody that binds to a glycosylated HEG1 protein obtained from mesothelioma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The purpose of the present invention is to provide an antibody that specifically binds to an N-terminus-side fragment of EphA2 cut by MT1-MMP, the antibody binding to the protein of (a) but not to the proteins of (b) and (c), where: (a) is a protein comprising an amino acid sequence represented by amino acids 28 to X (in this instance, X is an integer of 328 to 435; likewise hereunder) in an amino acid sequence represented by SEQ ID NO: 1; a protein comprising an amino acid sequence in which one or a plurality of amino acids have been added, substituted, inserted, or deleted in the amino acid sequence represented by amino acids 28 to X in the amino acid sequence represented by SEQ ID NO: 1; or a protein comprising an amino acid sequence that has 80% or more sequence identity with the amino acid sequence represented by amino acids 28 to X in the amino acid sequence represented by SEQ ID NO: 1; (b) is a protein comprising an amino acid sequence represented by amino acids 28 to 976 in the amino acid sequence represented by SEQ ID NO: 1; a protein comprising an amino acid sequence in which one or a plurality of amino acids have been added, substituted, inserted, or deleted in the amino acid sequence represented by amino acids 28 to 976 in the amino acid sequence represented by SEQ ID NO: 1; or a protein comprising an amino acid sequence that has 80% or more sequence identity with the amino acid sequence represented by amino acids 28 to 976 in the amino acid sequence represented by SEQ ID NO: 1; and (c) is a protein comprising an amino acid sequence represented by SEQ ID NO: 3; a protein comprising an amino acid sequence in which one or a plurality of amino acids have been added, substituted, inserted, or deleted in the amino acid sequence represented by SEQ ID NO: 3; or a protein comprising an amino acid sequence that has 80% or more sequence identity with the amino acid sequence represented by SEQ ID NO: 3.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
Disclosed is a novel diagnosis support means that has excellent performance of diagnosing a lesion in a lung field such as interstitial pneumonia and enables differentiation between IPF and NSIP which has been regarded as very difficult. The diagnosis support system according to the present invention for a lesion in a lung filed comprises: an image acquisition unit for acquiring a breast tomographic image obtained by photographing a subject; a lung peripheral region extraction unit for, from the breast tomographic image, extracting a peripheral region of the lung at an arbitrarily preset depth from the pleural surface; a feature amount acquisition unit for acquiring one or more feature amounts from the lung peripheral region; a lesion identification unit for identifying a lesion within the lung peripheral region on the basis of the one or more feature amounts acquired above; and an output unit for outputting the result of the lesion identification.
Provided are an antibody for detecting mesothelioma and an antibody having a high specificity to mesothelioma and a high sensitivity thereto. Also provided are a method for diagnosing mesothelioma using the aforesaid antibody, a reagent for diagnosing mesothelioma which comprises the aforesaid antibody, and a kit for diagnosing mesothelioma which comprises the aforesaid antibody. Also provided is a marker for diagnosing mesothelioma. Also provided is a medicinal composition to be used for treating mesothelioma, said pharmaceutical composition comprising the antibody according to the present invention or an antigen-binding fragment thereof. An antibody capable of binding to a sugar chain-modified HEG1 protein obtained from mesothelioma.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A technique is provided which enables simple and low-cost purification of biologically active proteins by means of a conjugate of a target substance capturing molecule and a protein which comprises the amino acid sequence in SEQ ID NO: 1, or a protein which comprises the amino acid sequence obtained by deleting, substituting or adding one or multiple amino acids in the amino acid sequence in SEQ ID NO: 1 and which has binding activity to a compound having -OH or -OR1 [R1 represents a hydrogen atom, an alkyl group or -PO3H2].
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Provided is a method for discriminating, at a molecular level, between non-metastatic endometrial cancer and endometrial cancer possibly metastatic to the lymph nodes. This method for assessing endometrial cancer metastasis to the lymph nodes or lymph node metastatic potential of endometrial cancer includes a step for measuring, in a biological sample derived from isolated cancer cells from an endometrial cancer patient, the level of expression of at least one expression product of DNA including a transcription start region, wherein said DNA comprises a base at any position in the transcription start region of a base sequence indicated by SEQ ID NO: 1-277 and at least one base continuing downstream therefrom, and said transcription start region is a region in which both ends thereof are specified by the first base of the base sequence indicated by SEQ ID NO: 1-277 and the 101th base from the 3' end.
The present invention relates to: an antigen peptide originated from a T790M point-mutated sequence of an EGFR; and a medicinal agent for treating cancer, which comprises the peptide.
The purpose of the present invention is to provide a method that can accurately detect DNA having a microsatellite region without causing the problem of non-specific reaction products. The present invention relates to a "method for detecting DNA having a microsatellite region by (1) bringing a probe, which does not have a nucleotide sequence complementary to the microsatellite region and which will hybridize with the nucleotide sequences on both sides of the microsatellite region, into contact with DNA having the microsatellite region, and forming a hybrid of the probe and the DNA, said hybrid having a loop structure containing the microsatellite region, (2) separating the obtained hybrid, and (3) detecting the hybrid", and a "hybrid of a probe and DNA, said hybrid having a loop structure containing a microsatellite region and obtained by bringing a probe, which does not have a nucleotide sequence complementary to the microsatellite region and which will hybridize with the nucleotide sequences on both sides of the microsatellite region, into contact with DNA having the microsatellite region".
The present invention addresses the problem of improving separation performance in separating a hybrid of a mutant DNA and a probe and/or a hybrid of a wild type DNA and a probe, said hybrids being obtained by the LH method. A method for the detection of a mutant DNA and/or a wild type DNA, said method comprising: step (1) for bringing into contact at least one kind of a single-stranded DNA (mutant DNA) having a substituted base, a deleted base region or an inserted base region, and/or a corresponding wild type single-stranded DNA (wild type DNA), with a probe that is hybridizable with both of the single stranded DNAs to form a hybrid (mutant hybrid) with the mutant DNA and/or a hybrid (wild type hybrid) with the wild type DNA, provided that the obtained mutant hybrid and/or wild-type hybrid have a loop structure; step (2) for bringing into contact the obtained mutant hybrid and/or wild type hybrid with an intercalator; and step (3) for separating a conjugate of the mutant hybrid with the intercalator and/or the conjugate of the wild-type hybrid with the intercalator to thereby detect the presence or absence of the mutant DNA and/or the wild type DNA.
(B2) a nucleic acid molecule that is capable of binding to c-Met and includes a base sequence obtained by substitution, deletion, addition, and/or insertion of one or more bases in the base sequence of any one of SEQ ID NOs: 39 to 76.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Provided is a cell concentration/purification device, said device having a function of successively arranging cells in a specific area of a microchannel continuously, and a function of successively taking cell images with the use of lights from a plurality of monochromatic light sources on an image base, then comparing and analyzing the images and thus recognizing the individual cells, in a single cell unit, on the basis of the data of the shape of the cells and the absorption spectrum distribution of the cells or in the cells to thereby selectively separate and purify the cells.
G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
The present invention relates to a method for detecting mutant DNA using a probe, and is characterized in comprising the steps of: (1) bringing into contact a sample containing single-stranded DNA (mutant DNA) having a substituted base, a deleted base region, or an inserted base region, and/or containing a corresponding wild-type single-stranded DNA (wild-type DNA), and a probe for hybridization with both of the single stranded DNAs, and forming a hybrid (mutant hybrid) with the mutant DNA and/or a hybrid (wild-type hybrid) with the wild-type DNA, the obtained mutant hybrid and/or wild-type hybrid having a stem structure; (2) separating the obtained mutant hybrid and/or wild-type hybrid by electrophoresis according to the presence or absence of the stem structure or differences in the stem structures; and (3) detecting the presence or absence of the mutant DNA in the sample.
Provided are: a nucleic acid molecule capable of binding to c-Met, which is a substance that can be used for analysis of the mechanism of development, diagnosis and treatment of diseases that are induced by c-Met; and use of the nucleic acid molecule capable of binding to c-Met. This nucleic acid molecule capable of binding to c-Met is any one of the following nucleic acid molecules (A1), (A2), (B1) and (B2). (A1) a nucleic acid molecule which comprises one of the nucleotide sequences represented by SEQ ID NOS: 1-38 (A2) a nucleic acid molecule which comprises a nucleotide sequence that is produced by substituting, deleting, adding or inserting one or more nucleotides in one of the nucleotide sequences represented by SEQ ID NOS: 1-38 and which is capable of binding to c-Met (B1) a nucleic acid molecule which comprises one of the nucleotide sequences represented by SEQ ID NOS: 39-76 (B2) a nucleic acid molecule which comprises a nucleotide sequence that is produced by substituting, deleting, adding or inserting one or more nucleotides in one of the nucleotide sequences represented by SEQ ID NOS: 39-76 and which is capable of binding to c-Met
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Provided are a prediction device, prediction method, program, and recording medium with which it is possible to easily predict whether or not a target aptamer sequence is enriched. A prediction device (10) comprises an input means (11), a calculation means (12), and a prediction means (13). The input means (11) inputs the sequence of a control aptamer sequence group that contains a control aptamer sequence and an aptamer sequence group to be compared that contains a selected aptamer of a pool to be compared. The calculation means (12) calculates the free energy of the aptamer sequence group to be compared and the control aptamer sequence group. The prediction means (13) compares the free energy of the two sequence groups and predicts that the pool to be compared is an enriched pool if the free energy of the aptamer sequence group to be compared is lower than that of the control aptamer sequence group. The control aptamer sequence group is a candidate aptamer sequence group containing multiple candidate aptamer sequences or a hypothetical aptamer sequence group derived from the aptamer sequence group to be compared containing hypothetical aptamer sequences of the same base composition as the aptamer sequence group to be compared.
Disclosed are a nucleic acid molecule which is capable of binding to HMGB1 protein, and a use of the nucleic acid molecule. Specifically, a nucleic acid molecule having a dissociation constant for HMGB1 protein of 5 × 10-7 or less can be used as a nucleic acid molecule that is capable of binding to HMGB1 protein. Since the nucleic acid molecule capable of binding to HMGB1 protein is able to bind to HMGB1 protein, which is known as a cause of diseases such as cancers and inflammation, preventive and curative effects on such diseases can be attained by having the nucleic acid molecule bound to HMGB1 protein in vivo.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
Provided is an aptamer that can bind to histidine peptide. A nucleic acid (a), (b), (c) or (d) below is used as an aptamer that can bind to histidine peptide. (a) A a nucleic acid containing a base sequence represented by GGUNnAYUmGGH. Here, N represents A, G, C, U or T, the n of Nn is the number of N and is an integer from 1 to 3, Y represents U, T or C, the m of Um is the number of U, and is an integer from 1 to 3, and H represents U, T, C, or A. (b) A nucleic acid containing a base sequence obtained by substituting, deleting, adding or inserting one or more bases to the base sequence (a), and which is capable of bonding to the aforementioned histidine peptide. (c) A nucleic acid containing a base sequence represented by GGCGCCUUCGUGGAAUGUC. (d) A nucleic acid containing a base sequence obtained by substituting, deleting, adding or inserting one or more bases to the base sequence (c), and which is capable of bonding to the aforementioned histidine peptide.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
patents
